Patients in Cyprus are waiting more than 500 days on average to access new medicines, one of the longest delays in Europe, as officials warned on Friday that the EU is falling behind global competitors in pharmaceutical innovation and access.
Speaking at a conference in Nicosia titled ‘Unlocking Europe’s Life Science Potential: A Policy Agenda for Competitiveness, Innovation and Patient Access’, Cyprus and European officials said patients face growing delays in accessing new treatments, while Europe risks losing ground in global pharmaceutical investment.
Cyprus Energy, Commerce and Industry Minister Michael Damianos said the EU must act urgently to boost competitiveness and ensure faster access to medicines, particularly for smaller member states such as Cyprus.
‘The evidence is clear,’ he said, noting that the EU’s share of global clinical trial starts has fallen to around 12%, compared with about 30% in China. ‘This is not simply a statistic – it means fewer opportunities for European patients to access innovative treatments early,’ Damianos noted.
He added that it takes on average around 24 months for new medicines to reach patients in Europe, compared with just four months in the United States.
‘For patients waiting for life-saving therapies, these delays are not administrative – they are deeply personal and often critical,’ he said.
Damianos outlined four priorities for EU policy: strengthening research and development incentives, modernising regulatory systems, improving access across member states and accelerating digital transformation in healthcare.
‘No patient should wait years for treatment simply because of where they live,’ he said.
Earlier, Nathalie Moll, Director-General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), said access to medicines in Cyprus has deteriorated, with average waiting times rising from more than 400 days in 2022 to over 500 days today.
‘Access to medicines remains a real challenge in Cyprus,’ she said.
Preliminary findings from EFPIA’s Patients WAIT Indicator Survey show some improvement in availability, with Cyprus rising from 29% to 39%, just below the EU average of 45%, though the gap remains significant.
Moll said access delays stem from multiple factors, including regulatory, pricing and reimbursement processes, as well as underinvestment in innovative medicines. Smaller markets such as Cyprus face additional challenges, including infrastructure constraints, limited patient populations for orphan drugs and funding gaps for advanced therapies.
She added that while companies aim to bring medicines to patients quickly, national procedures play a decisive role in delays.
In his address, Cyprus Health Minister Neophytos Charalambides said ensuring fair and timely access to medicines is a key priority of the Cyprus Presidency of the Council of the EU.
‘In this context, our key word is autonomy,’ he said, referring to the EU’s ability to guarantee access to medicines and healthcare even in times of crisis.
He stressed that improving availability, affordability and accessibility of medicines, alongside strengthening health system resilience, is central to policy efforts, while innovation must reach patients in all member states without delay.
‘Medical innovation achieves its full value only when it reaches the people who need it,’ he said.
In a video message, European Commissioner for Health and Animal Welfare Olivér Várhelyi said EU reforms aim to strengthen the life sciences sector and speed up access to innovation.
He highlighted the proposed Biotech Act and broader pharmaceutical reform, describing it as the most significant overhaul of EU medicines legislation in more than 20 years.
Opening the event, KEFEA President Kyriakos Mikellis said Europe must ensure its policy environment keeps pace with scientific progress, stressing the need for alignment between national and EU priorities.
The conference, held under the auspices of the Cyprus EU Presidency, brought together policymakers, industry and healthcare stakeholders to discuss strengthening Europe’s life sciences sector while ensuring equitable patient access.